Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mark Fereshteh"'
Autor:
Wei Han, Matthew Loya, Omar Jabado, Patrick Franken, Nora Pencheva, Mark Fereshteh, Chung-Wein Lee, Clifton Drew, Louise Koopman, Angelo Harris, Mohammed Qutaish, Brooke Robertson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a1f43e7e503f4d43b6419599f2f2b8e2
Autor:
Matthew Loya, Homer Adams, Omar Jabado, Patrick Franken, Nora Pencheva, Mark Fereshteh, Li Fan, Anantharaman Muthuswamy, Angelo Harris, Susan Sun, Gabrielle Suppa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7403e914b9eb4aa7beb2906baa405205
Autor:
Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/026b8577fc804412a127d45c0c573c04
Autor:
Omar Jabado, Suzana Couto, Patricia Coutinho de Souza, Kate Sasser, Mark Fereshteh, Li Fan, Angelo Harris, Arturo Chaparro, Mohammed Qutaish, Han Si, Jan-Hermen Dannenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6f2d7ef7821f4dcb9279e88c4383277b
Autor:
Maria Jure-Kunkel, Rachelle Kosoff, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/eea14f7713674c8fb51f93a571e8bfb1
Autor:
Jinqi Liu, Joshua Curtin, Dan You, Stephen Hillerman, Bifang Li-Wang, Rukiye Eraslan, Jenny Xie, Jesse Swanson, Ching-Ping Ho, Simone Oppenheimer, Bethanne M Warrack, Colleen A McNaney, David M Nelson, Jordan Blum, Taeg Kim, Mark Fereshteh, Michael Reily, Petia Shipkova, Anwar Murtaza, Miguel Sanjuan, John T Hunt, Luisa Salter-Cid
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0212670 (2019)
Immunotherapy has fundamentally changed the landscape of cancer treatment. Despite the encouraging results with the checkpoint modulators, response rates vary widely across tumor types, with a majority of patients exhibiting either primary resistance
Externí odkaz:
https://doaj.org/article/7604dc75ad594b68a709196c2f123df0
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77571654a67b8230111048825587e8ec
https://doi.org/10.1158/2159-8290.c.6549569
https://doi.org/10.1158/2159-8290.c.6549569
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e568b16421048c1e79b8dfceca7e687
https://doi.org/10.1158/2159-8290.22541198.v1
https://doi.org/10.1158/2159-8290.22541198.v1
Supplementary Methods and Figures 1-3 from Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e4d407057341888fc39c55e65e6ca7
https://doi.org/10.1158/0008-5472.22367858.v1
https://doi.org/10.1158/0008-5472.22367858.v1
The steroid receptor coactivator amplified in breast cancer 1 (AIB1) as well as epidermal growth factor receptor (EGFR) family members are frequently overexpressed in epithelial tumors, and their expression is associated with poor prognosis. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f9e0aacbaa1c1b1b3ce150621ec6dc
https://doi.org/10.1158/0008-5472.c.6495719
https://doi.org/10.1158/0008-5472.c.6495719